Health
Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients – News-Medical.Net
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), acco…
Reviewed by Emily Henderson, B.Sc.Oct 1 2020
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.
The findings, from a global randomized phase 3 clinical trial published today in the New England Journal of Medicine, support the U.S. Food and Drug Administration’s approval of the drug for this indication in May.
These are e…
-
Business23 hours agoWhy this fantastic blue chip ASX 200 share could rise 20%
-
General22 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
Noosa News14 hours agoDog daycare program a TikTok hit for helping disabled find work, friends
-
General16 hours agoPhotographers reveal iconic image of Gough Whitlam and Vincent Lingiari was posed on Wave Hill Walk-Off anniversary